Therefore, further large-scale prospective clinical trials and basic research studies are required to elucidate the relationship between plasmatic levels of HSP90α at diagnosis and poor prognosis in advanced lung cancer patients treated with PD1/PD-L1 inhibitors plus chemotherapy. Here, PDCD1 is linked to lung carcinoma.